The role of dihydrosphingolipids in disease

Ruth R. Magaye; Feby Savira; Yue Hua; Darren J. Kelly; Christopher Reid; Bernard Flynn; Danny Liew; Bing H. Wang

doi:10.1007/s00018-018-2984-8

The role of dihydrosphingolipids in disease

Ruth R. Magaye, Feby Savira, Yue Hua, Darren J. Kelly, Christopher Reid, Bernard Flynn, Danny Liew, Bing H. Wang

Research output: Contribution to journal › Review Article › Research › peer-review

32 Citations (Scopus)

Abstract

Dihydrosphingolipids refer to sphingolipids early in the biosynthetic pathway that do not contain a C4-trans-double bond in the sphingoid backbone: 3-ketosphinganine (3-ketoSph), dihydrosphingosine (dhSph), dihydrosphingosine-1-phosphate (dhS1P) and dihydroceramide (dhCer). Recent advances in research related to sphingolipid biochemistry have shed light on the importance of sphingolipids in terms of cellular signalling in health and disease. However, dihydrosphingolipids have received less attention and research is lacking especially in terms of their molecular mechanisms of action. This is despite studies implicating them in the pathophysiology of disease, for example dhCer in predicting type 2 diabetes in obese individuals, dhS1P in cardiovascular diseases and dhSph in hepato-renal toxicity. This review gives a comprehensive summary of research in the last 10–15 years on the dihydrosphingolipids, 3-ketoSph, dhSph, dhS1P and dhCer, and their relevant roles in different diseases. It also highlights gaps in research that could be of future interest.

Original language	English
Pages (from-to)	1107-1134
Number of pages	28
Journal	Cellular and Molecular Life Sciences
Volume	76
Issue number	6
DOIs	https://doi.org/10.1007/s00018-018-2984-8
Publication status	Published - Mar 2019

Keywords

4-HRP fenretinide
Adipocyte
Aging
Airway hypersensitivity
Apoptosis
Autophagy
Cancer
Cardiomyopathy
Ceramide
Ceramide synthase
Diabetes
Dihydroceramide desaturase 1-Des-1
Dihydrosphinganine
FB1 toxicity
Hypoxia
Neurodegenerative
Serine palmitoyl transferase
Sphingosine kinase
Sphingosine-1-phosphate receptors
Sphingosine-1-phosphate—S1P

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00018-018-2984-8

Cite this

@article{50fc4917b5bd4bc4aa60be3dd7786940,

title = "The role of dihydrosphingolipids in disease",

abstract = "Dihydrosphingolipids refer to sphingolipids early in the biosynthetic pathway that do not contain a C4-trans-double bond in the sphingoid backbone: 3-ketosphinganine (3-ketoSph), dihydrosphingosine (dhSph), dihydrosphingosine-1-phosphate (dhS1P) and dihydroceramide (dhCer). Recent advances in research related to sphingolipid biochemistry have shed light on the importance of sphingolipids in terms of cellular signalling in health and disease. However, dihydrosphingolipids have received less attention and research is lacking especially in terms of their molecular mechanisms of action. This is despite studies implicating them in the pathophysiology of disease, for example dhCer in predicting type 2 diabetes in obese individuals, dhS1P in cardiovascular diseases and dhSph in hepato-renal toxicity. This review gives a comprehensive summary of research in the last 10–15 years on the dihydrosphingolipids, 3-ketoSph, dhSph, dhS1P and dhCer, and their relevant roles in different diseases. It also highlights gaps in research that could be of future interest.",

keywords = "4-HRP fenretinide, Adipocyte, Aging, Airway hypersensitivity, Apoptosis, Autophagy, Cancer, Cardiomyopathy, Ceramide, Ceramide synthase, Diabetes, Dihydroceramide desaturase 1-Des-1, Dihydrosphinganine, FB1 toxicity, Hypoxia, Neurodegenerative, Serine palmitoyl transferase, Sphingosine kinase, Sphingosine-1-phosphate receptors, Sphingosine-1-phosphate—S1P",

author = "Magaye, {Ruth R.} and Feby Savira and Yue Hua and Kelly, {Darren J.} and Christopher Reid and Bernard Flynn and Danny Liew and Wang, {Bing H.}",

year = "2019",

month = mar,

doi = "10.1007/s00018-018-2984-8",

language = "English",

volume = "76",

pages = "1107--1134",

journal = "Cellular and Molecular Life Sciences",

issn = "1420-682X",

publisher = "Birkhauser",

number = "6",

}

TY - JOUR

T1 - The role of dihydrosphingolipids in disease

AU - Magaye, Ruth R.

AU - Savira, Feby

AU - Hua, Yue

AU - Kelly, Darren J.

AU - Reid, Christopher

AU - Flynn, Bernard

AU - Liew, Danny

AU - Wang, Bing H.

PY - 2019/3

Y1 - 2019/3

N2 - Dihydrosphingolipids refer to sphingolipids early in the biosynthetic pathway that do not contain a C4-trans-double bond in the sphingoid backbone: 3-ketosphinganine (3-ketoSph), dihydrosphingosine (dhSph), dihydrosphingosine-1-phosphate (dhS1P) and dihydroceramide (dhCer). Recent advances in research related to sphingolipid biochemistry have shed light on the importance of sphingolipids in terms of cellular signalling in health and disease. However, dihydrosphingolipids have received less attention and research is lacking especially in terms of their molecular mechanisms of action. This is despite studies implicating them in the pathophysiology of disease, for example dhCer in predicting type 2 diabetes in obese individuals, dhS1P in cardiovascular diseases and dhSph in hepato-renal toxicity. This review gives a comprehensive summary of research in the last 10–15 years on the dihydrosphingolipids, 3-ketoSph, dhSph, dhS1P and dhCer, and their relevant roles in different diseases. It also highlights gaps in research that could be of future interest.

AB - Dihydrosphingolipids refer to sphingolipids early in the biosynthetic pathway that do not contain a C4-trans-double bond in the sphingoid backbone: 3-ketosphinganine (3-ketoSph), dihydrosphingosine (dhSph), dihydrosphingosine-1-phosphate (dhS1P) and dihydroceramide (dhCer). Recent advances in research related to sphingolipid biochemistry have shed light on the importance of sphingolipids in terms of cellular signalling in health and disease. However, dihydrosphingolipids have received less attention and research is lacking especially in terms of their molecular mechanisms of action. This is despite studies implicating them in the pathophysiology of disease, for example dhCer in predicting type 2 diabetes in obese individuals, dhS1P in cardiovascular diseases and dhSph in hepato-renal toxicity. This review gives a comprehensive summary of research in the last 10–15 years on the dihydrosphingolipids, 3-ketoSph, dhSph, dhS1P and dhCer, and their relevant roles in different diseases. It also highlights gaps in research that could be of future interest.

KW - 4-HRP fenretinide

KW - Adipocyte

KW - Aging

KW - Airway hypersensitivity

KW - Apoptosis

KW - Autophagy

KW - Cancer

KW - Cardiomyopathy

KW - Ceramide

KW - Ceramide synthase

KW - Diabetes

KW - Dihydroceramide desaturase 1-Des-1

KW - Dihydrosphinganine

KW - FB1 toxicity

KW - Hypoxia

KW - Neurodegenerative

KW - Serine palmitoyl transferase

KW - Sphingosine kinase

KW - Sphingosine-1-phosphate receptors

KW - Sphingosine-1-phosphate—S1P

UR - http://www.scopus.com/inward/record.url?scp=85058042941&partnerID=8YFLogxK

U2 - 10.1007/s00018-018-2984-8

DO - 10.1007/s00018-018-2984-8

M3 - Review Article

C2 - 30523364

AN - SCOPUS:85058042941

SN - 1420-682X

VL - 76

SP - 1107

EP - 1134

JO - Cellular and Molecular Life Sciences

JF - Cellular and Molecular Life Sciences

IS - 6

ER -

The role of dihydrosphingolipids in disease

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Novel approaches to the prevention and treatment of chronic heart disease and its co-morbid complications

Mechanisms underlying the contribution of uremic toxins to cardiorenal syndrome

Cite this

The role of dihydrosphingolipids in disease

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Projects

Novel approaches to the prevention and treatment of chronic heart disease and its co-morbid complications

Mechanisms underlying the contribution of uremic toxins to cardiorenal syndrome

Cite this